Dream phenomena induced by chronic levodopa therapy
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Twenty-seven of eighty-eight (30.7%) Parkinsonian patients on chronic levodopa or levodopa/carbidopa therapy developed drug related dream phenomena. The patients reported three separate types of new dreams which we have classified as vivid dreams, night terrors and nightmares. These dreams are correlated to the duration of levodopa therapy although the mechanism of their production is unclear.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Broughton, R. J. (1968) · Science · doi:10.1126/science.159.3819.1070 · Cited by 637
Dream reports from different stages of sleep
Foulkes, W. D. (1962) · The Journal of Abnormal and Social Psychology · doi:10.1037/h0040431 · Cited by 563
(1973) · Elsevier eBooks · doi:10.1016/b978-0-120-78150-8.x5001-4 · Cited by 539
L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
Barbeau, A. (1969) · PubMed · Cited by 410
Levodopa-induced psychosis: a kindling phenomenon
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.6.669 · Cited by 326
Self-citationMental activity at sleep onset.
Foulkes, D., & Vogel, G. (1965) · Journal of Abnormal Psychology · doi:10.1037/h0022217 · Cited by 318
Sleep Disorders: Recent Findings in the Diagnosis and Treatment of Disturbed Sleep
Kales, A., & Kales, J. D. (1974) · New England Journal of Medicine · doi:10.1056/nejm197402282900905 · Cited by 178
Kales, A., Ansel, R. D., Markham, C. H., Scharf, M. B., & Tan, T.-L. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part2397 · Cited by 169
Psychosis and Other Psychiatric Manifestations of Levodopa Therapy
Celesia, G. G., & Barr, A. N. (1970) · Archives of Neurology · doi:10.1001/archneur.1970.00480270003001 · Cited by 167
The nature of the narcoleptic sleep attack
Dement, W., Rechtschaffen, A., & Gulevich, G. (1966) · Neurology · doi:10.1212/wnl.16.1.18 · Cited by 163
Research works printed but not linked: 7
- Barbeau, A. L-dopa therapy in Parkinsons disease a critical review of Hines years experience. Can. Med. Assoc. J.101, 59–68 (1969).
- Goodwin, F. K. Behavioral effects of levodopa in man. Semin. Psychiatry3, 477–492 (1971).
- Kales, A., Scharf, M., Tan, T. L. Sleep laboratory and clinical studies of the effects of Tofranil, Valium, and placebo on sleep stages and enuresis. Psychophysiology7, 350–352 (1970).
- Klawans, H. L., Garvin, J. S. Treatment of Parkinsonian with L-dopa. Dis. Nerv. Syst.30, 733–746 (1969).
- Post, R. M., Gillin, J. C., Wyatt, R. J., Goodwin, F. K., Snyder, F., Bunney, W. E. REM sleep suppressing effects of intravenous L-dopa given during sleep. Psychophysiology9, 88 (1972).
- Schmidt, H. S., Knopp, W. Sleep in Parkinson's disease: The effect of L-dopa. Psychophysiology9, 88 (1972).
- Spitzer, H., Zarcone, V., Barchas, J., Ryan, R., Smythe, H., Dement, W. Administration of 5-hydroxytryptophan (5-HTP) to a L-dihydroxy-phenylamine (L-dopa) treated patient with Shy-Drager syndrome. Psychophysiology9, 87 (1972).
Cited by
Items 101–136 of 136
Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases
Heller, N. H., Barrett, F. S., Buchborn, T., Collerton, D., Dupuis, D., Halberstadt, A. L., Jardri, R., Noorani, T. N., Preller, K. H., Taylor, J., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf068 · Cited by 3
L'interprétation des rêves et les neurosciences
Solms, M. (2019) · Journal de la psychanalyse de l enfant · doi:10.3917/jpe.017.0007 · Cited by 4
Chapter 21 The nocturnal manifestations of waking movement disorders: focus on Parkinson's disease
Rye, D. B., & Iranzo, Á. (2005) · Handbook of clinical neurophysiology · doi:10.1016/s1567-4231(09)70046-2 · Cited by 3
Drugs affecting autonomic functions or the extrapyramidal system
Karch, F. E. (1980) · Side effects of drugs annual · doi:10.1016/s0378-6080(80)80017-1 · Cited by 3
Use of Olanzapine in Anorexia Nervosa
Menaster, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0519a · Cited by 3
Medical Conditions and Diseases
Rogers, N. L., & Kloss, J. D. (2004) · CRC Press eBooks · doi:10.3109/9780203998007-6 · Cited by 3
Trying to understand sleep in Parkinson's disease patients*
Askenasy, J. J. M. (2005) · Sleep and Biological Rhythms · doi:10.1111/j.1479-8425.2005.00156.x · Cited by 2
Psychosis in Parkinson's Disease
Friedman, J. H. (2011) · Parkinson s Disease · doi:10.1002/9781444397970.ch16 · Cited by 2
Influence du sommeil sur les mouvements anormaux de la veille
Autret, A., Lucas, B., Henry, F., Saudeau, D., & de Toffol, B. (1994) · Neurophysiologie Clinique · doi:10.1016/s0987-7053(05)80186-8 · Cited by 2
Injection Site Pain With Long-Acting Risperidone
Pinninti, N. R., & Mago, R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0519c · Cited by 2
Sleep Disorders in Parkinson’s Disease and Parkinsonian Syndromes
Georgsson, H., & Murray, B. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1703-7.10026-x · Cited by 1
Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial
Roepke, S., Schoofs, N., Priebe, K., Wülfing, F., Meyer, K., Gieselmann, A., Stieglbauer, K., Gómez, M. G., Biedermann, S. V., Gallinat, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04546-9 · Cited by 2
Medical Conditions and Diseases
Rogers, N. L., & Kloss, J. D. (2004) · Lung biology in health and disease · doi:10.1201/b14100-7 · Cited by 1
Cognitive and Psychiatric Aspects of Parkinson’s Disease: Treatment Recommendations
Menza, M. A., Dobkin, R. D., & Marín, H. (2006) · Aging Health · doi:10.2217/1745509x.2.1.87 · Cited by 1
Jain, K. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-73503-6_18 · Cited by 1
Reply to Injection Site Pain With Long-Acting Risperidone
Lindenmayer, J., Eerdekens, E., & Eerdekens, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0519d · Cited by 1
Dopaminerg-induzierte Psychosen und Halluzinationen bei Morbus Parkinson
Bittkau, S. (2002) · Steinkopff eBooks · doi:10.1007/978-3-642-57512-9_14 · Cited by 1
Therapeutic and adverse drug effects
Mollayeva, T., & Shapiro, C. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822963-7.00023-2 · Cited by 1
Insomnia in Primary Sleep Disorders
Duntley, S. P. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-662-1_12
Sleep and lesions in the central nervous system
Autret, A. (2003) · Springer eBooks · doi:10.1007/978-1-4615-0217-3_57
Reply to Use of Olanzapine in Anorexia Nervosa
Barbarich-Marsteller, N. C., & Kaye, W. H. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0519b
Schwalen, S., Leclaire, J., Rechlin, M., & Jörg, J. (1997) · European Journal of Neurology · doi:10.1111/j.1468-1331.1997.tb00362.x
Detección y manejo de síntomas no motores en la enfermedad de Parkinson: impacto en su prevalencia
Rodríguez‐Violante, M., & Cervantes‐Arriaga, A. (2011) · Revista médica de Chile · doi:10.4067/s0034-98872011000800008
Management of Psychiatric Symptoms in Parkinson’s Disease
Klawans, H. L., & Tanner, C. M. (1989) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-73899-9_23
Self-citationSleep Disturbances in Parkinson's Disease
Talaat, F. M., El-Kader, A. A. A., Rabah, A. M., Shamloul, R. M., & Afifi, L. (2010)
Brain Oscillations and Predictive Coding: What We Know and What We Should Learn
Scarpelli, S., D’Atri, A., Gorgoni, M., Gennaro, L. D., & Ferrara, M. (2017) · Frontiers research topics · doi:10.3389/978-2-88945-161-6
“Consistently, empirical evidences have underlined that the chemical stimulation of this area by -dopa elicits psychotic symptoms, nightmares andmore vivid dream contents (Scharf et al., 1978; Nausieda et al., 1982).”
BackgroundReply to: Correlation of Antidepressant Use and Symptom Time Period in Dream Enactment Behaviors
Otaiku, A. I. (2021) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13377
The Pharmacostrategy of Treating Sleep Disorders in Parkinsonism
Askenasy, J. J. M. (2006) · Springer eBooks · doi:10.1007/0-387-27682-3_26
Siclari, F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822963-7.00119-5 · Cited by 1
Out-of-Body and Near-Death Experiences
Marks, D. F. (2020) · SAGE Publications Ltd eBooks · doi:10.4135/9781529730036.n10
Pellegrini, E., Scarpelli, S., Alfonsi, V., Gorgoni, M., Pazzaglia, M., & Gennaro, L. D. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106012
Visual Hallucinations in Serotonergic Psychedelics and Lewy Body DiseasesPreprint
Heller, N. H., Barrett, F. S., Buchborn, T., Collerton, D., Dupuis, D., Halberstadt, A. L., Jardri, R., Noorani, T. N., Preller, K. H., Taylor, J., et al. (2025) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/7x8q4_v3
The effects of RBD medications on dream content: A critical review of evidence
Bontempi, G., Capriglia, E., Bernardi, G., & Elce, V. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106878
Neumane, S. (2011) · theses.fr (ABES) · doi:10.70675/4cb9b747z6b13z46eazb3cbzb58a8bffabf2
Bugalho, P. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09246-3
“We did not find a significant influ - ence of dopaminergic treatment doses in observer dreams frequency, as could be expected given the link between vivid dreams and dopaminergic treatment referred in early studies [5 ].”
Subjective Assessment of Sleep and Sleepiness in Parkinson’s Disease
Santamaría, J. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1631-9_5
Metadata
- Authors
- Sharf, B., Moskovitz, C., Lupton, M. D., & Klawans, H. L.
- Affiliations
- Bnai Zion Medical Center (IL)
- Rush University Medical Center (US)
- Venue
- Journal of Neural Transmission
- Published
- 1978-06
- Volume
- 43
- Issue
- 2
- Pages
- 143-151
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2049922305
- Cited by
- 137
- References
- 29
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 2 · 2013: 4 · 2012: 2
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Parkinsonfonden
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Restless Legs Syndrome Research
- Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
- Keywords
- levodopa, levodopa/carbidopa, Parkinson's disease, vivid dreams, night terrors, nightmares, adverse drug reactions, treatment duration
- MeSH terms
- Adult, Aged, Carbidopa, Delusions, Dreams, Female, Hallucinations, Humans, Illusions, Levodopa, Long-Term Care, Male, Middle Aged, Parkinson Disease, Psychoses, Substance-Induced
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.